PTCT
PTC THERAPEUTICS, INC.
$75.14
+0.58%
$6.2B
No data for this timeframe.
Vol
Market Cap$6.2B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (76%)
Inst. Holders50 funds
Inst. Value$4.9B
Inst. Activity27 buys / 13 sells
Insider Activity0B / 21S
Insider Net $-$6.7M
SEC Reports8
Recent Activity
Jun 11, 2026
short_volume
Short Volume: PTCT — 86.6% short (1.0M / 1.2M)
Short: 998,323 | Exempt: 0 | TRF Vol: 1,153,298 | Short Ratio: 86.6% | Off-exchange volume (dark poo
Jun 10, 2026
Insider
Pauwels Eric sold 3,711 shares
CHIEF BUSINESS OFFICER @ $75.00 ($278.3K)
Jun 10, 2026
Insider
Pauwels Eric acquired via exercise 17,566 shares
CHIEF BUSINESS OFFICER @ $18.01 ($316.4K)
Jun 10, 2026
Insider
Pauwels Eric sold 17,566 shares
CHIEF BUSINESS OFFICER
Jun 9, 2026
SEC
Board member Alethia Young resigned effective June 8, 2026, citing a need to focus on other work commitments, with no di
8-K — Impact 2/10
May 19, 2026
SEC
Two insiders at PTC Therapeutics sold a combined $220K of stock shortly after a strong Q1 earnings beat and raised guida
CLUSTER — Impact 2/10
May 15, 2026
SEC
Two PTCT insiders, including CEO Matthew Klein, sold a combined ~$115K in open-market sales within a week of the company
CLUSTER — Impact 2/10
Inst.
JANUS HENDERSON GROUP PLC — ADD
7,193,433 shares ($490.0M)
Price Targets
$93.93
+25.0% upside
Strong Buy
Current $75.14
Low $65.00
Median $92.50
High $124.00
14 analysts
$65.00
$124.00
Analyst Ratings
5Strong Buy
11Buy
4Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Jefferies | UPGRADE | Hold → Buy |
| May 8, 2026 | TD Cowen | UPGRADE | Hold → Buy |
| May 8, 2026 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Mar 30, 2026 | Jefferies | DOWNGRADE | Buy → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.33 ▲ +172.5% | $0.28 — $0.43 | 140% YoY | 3 |
| Next Q | $0.47 ▲ +191.0% | $0.29 — $0.58 | 152% YoY | 3 |
| Current FY | $1.31 ▲ +166.7% | $0.85 — $1.71 | -83% YoY | 3 |
| Next FY | $2.78 ▲ +14.5% | $1.29 — $4.18 | 112% YoY | 3 |
Latest Reports
NEUTRAL
8-K
2/10
Board member Alethia Young resigned effective June 8, 2026, citing a need to focus on other work commitments, with no di
Jun 9, 2026
NEUTRAL
CLUSTER
2/10
Two insiders at PTC Therapeutics sold a combined $220K of stock shortly after a strong Q1 earnings beat and raised guida
May 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BlackRock, Inc. | $882.2M | ADD |
| RTW INVESTMENTS, LP | $527.8M | — |
| JANUS HENDERSON GROUP PLC | $490.0M | ADD |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $327.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Pauwels Eric | SELL | $278.3K |
| Jun 10, 2026 | Pauwels Eric | M | $316.4K |
| Jun 10, 2026 | Pauwels Eric | SELL | $0.00 |
| May 15, 2026 | Boulding Mark | M | $72.2K |
| May 15, 2026 | Boulding Mark | SELL | $169.8K |
50 institutional holders with $4.9B total value (71,972,716 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, RTW. Net buying activity: 27 institutions added/increased vs 13 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 12,948,717 | $882.2M | 18.0% | ADD +79.2% |
| 3 | RTW INVESTMENTS, LP | 7,746,415 | $527.8M | 10.8% | — |
| 4 | JANUS HENDERSON GROUP PLC | 7,193,433 | $490.0M | 10.0% | ADD +48.3% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,804,594 | $327.3M | 6.7% | — |
| 6 | STATE STREET CORP | 4,346,519 | $296.1M | 6.0% | ADD +34.2% |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 3,942,610 | $268.6M | 5.5% | — |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 3,676,256 | $250.5M | 5.1% | — |
| 9 | TORONTO DOMINION BANK | 3,025,963 | $206.2M | 4.2% | TRIM -26.9% |
| 10 | BANK OF AMERICA CORP /DE/ | 1,886,841 | $128.6M | 2.6% | ADD +31.8% |
| 11 | Hood River Capital Management LLC | 1,664,559 | $113.4M | 2.3% | ADD +65.9% |
| 12 | D. E. Shaw & Co., Inc. | 1,640,381 | $111.8M | 2.3% | — |
| 13 | FMR LLC | 1,528,362 | $104.1M | 2.1% | — |
| 14 | Pictet Asset Management Holding SA | 1,183,720 | $80.1M | 1.6% | TRIM -30.5% |
| 15 | FRANKLIN RESOURCES INC | 1,121,388 | $76.4M | 1.6% | — |
| 16 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,015,772 | $69.2M | 1.4% | — |
| 17 | DIMENSIONAL FUND ADVISORS LP | 890,715 | $60.7M | 1.2% | ADD +42.0% |
| 18 | Invesco Ltd. | 865,451 | $59.0M | 1.2% | ADD +99.3% |
| 19 | GOLDMAN SACHS GROUP INC | 827,631 | $56.4M | 1.1% | — |
| 20 | Woodline Partners LP | 744,988 | $50.8M | 1.0% | ADD +30.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | ADD | 4,851,332 | 7,193,433 | +48.3% | $490.0M | 2026-Q1 |
| TORONTO DOMINION BANK | TRIM | 4,138,215 | 3,025,963 | -26.9% | $206.2M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,431,557 | 1,886,841 | +31.8% | $128.6M | 2026-Q1 |
| Hood River Capital Management LLC | ADD | 1,003,075 | 1,664,559 | +65.9% | $113.4M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 627,092 | 890,715 | +42.0% | $60.7M | 2026-Q1 |
| Invesco Ltd. | ADD | 434,285 | 865,451 | +99.3% | $59.0M | 2026-Q1 |
| Woodline Partners LP | ADD | 571,553 | 744,988 | +30.3% | $50.8M | 2026-Q1 |
| JUPITER ASSET MANAGEMENT LTD | ADD | 361,159 | 711,457 | +97.0% | $48.5M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 905,192 | 674,134 | -25.5% | $45.9M | 2026-Q1 |
| LOOMIS SAYLES & CO L P | NEW | — | 493,603 | — | $33.6M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 247,746 | 460,638 | +85.9% | $31.4M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 460,564 | — | $31.4M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 236,909 | 345,683 | +45.9% | $23.6M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | TRIM | 647,585 | 311,810 | -51.9% | $21.2M | 2026-Q1 |
| HSBC HOLDINGS PLC | DOUBLED | 12,128 | 227,059 | +1772.2% | $15.5M | 2026-Q1 |
| FEDERATED HERMES, INC. | DOUBLED | 112,566 | 225,916 | +100.7% | $15.4M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 92,089 | 130,204 | +41.4% | $8.9M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 72,597 | 134,968 | +85.9% | $8.9M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 406,410 | 111,632 | -72.5% | $7.6M | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 32,421 | 71,660 | +121.0% | $4.9M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 46,775 | 68,988 | +47.5% | $4.7M | 2026-Q1 |
| PICTON MAHONEY ASSET MANAGEMENT | DOUBLED | 2,280 | 53,328 | +2238.9% | $3.6M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | TRIM | 75,400 | 50,506 | -33.0% | $3.4M | 2026-Q1 |
| Allspring Global Investments Holdings, LLC | DOUBLED | 12,185 | 47,871 | +292.9% | $3.3M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 7,412 | 42,172 | +469.0% | $2.9M | 2026-Q1 |
9 unique insiders with 30 transactions. Net insider value: -$6.7M ($0.00 bought, $6.7M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Pauwels Eric | CHIEF BUSINESS OFFICER | SELL | 3,711 | $75.00 | $278.3K |
| Jun 10, 2026 | Pauwels Eric | CHIEF BUSINESS OFFICER | EXERCISE | 17,566 | $18.01 | $316.4K |
| Jun 10, 2026 | Pauwels Eric | CHIEF BUSINESS OFFICER | SELL | 17,566 | — | — |
| May 15, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | EXERCISE | 2,812 | $25.69 | $72.2K |
| May 15, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | SELL | 2,356 | $72.08 | $169.8K |
| May 14, 2026 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 679 | $73.06 | $49.6K |
| May 13, 2026 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | AWARD | 12,500 | — | — |
| May 8, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | EXERCISE | 2,740 | $46.54 | $127.5K |
| May 8, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | SELL | 840 | $78.23 | $65.7K |
| Apr 21, 2026 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 2,850 | $70.91 | $202.1K |
| Apr 6, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | SELL | 822 | $68.91 | $56.6K |
| Apr 6, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | EXERCISE | 2,265 | $39.42 | $89.3K |
| Apr 2, 2026 | Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | SELL | 829 | $67.99 | $56.4K |
| Apr 1, 2026 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | SELL | 39,393 | $68.89 | $2.7M |
| Mar 24, 2026 | Chutter Jessica Caroline | Director | AWARD | 4,000 | — | — |
| Mar 24, 2026 | Chutter Jessica Caroline | Director | AWARD | 3,475 | — | — |
| Mar 12, 2026 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 2,662 | $64.08 | $170.6K |
| Mar 11, 2026 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | AWARD | 12,500 | — | — |
| Mar 10, 2026 | Okey Stephanie | Director | EXERCISE | 1,167 | $33.63 | $39.2K |
| Mar 10, 2026 | Okey Stephanie | Director | SELL | 1,167 | $70.00 | $81.7K |
| Mar 5, 2026 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | SELL | 3,989 | $63.38 | $252.8K |
| Mar 5, 2026 | Okey Stephanie | Director | SELL | 6,333 | $63.38 | $401.4K |
| Mar 5, 2026 | Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | SELL | 10,000 | $63.38 | $633.8K |
| Feb 19, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | SELL | 588 | $68.54 | $40.3K |
| Feb 18, 2026 | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | SELL | 2,494 | $69.36 | $173.0K |
| Feb 18, 2026 | Gravier Pierre | CHIEF FINANCIAL OFFICER | SELL | 2,992 | $69.36 | $207.5K |
| Feb 18, 2026 | Pauwels Eric | CHIEF BUSINESS OFFICER | SELL | 3,019 | $69.36 | $209.4K |
| Feb 18, 2026 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 7,371 | $69.36 | $511.3K |
| Feb 18, 2026 | Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | SELL | 2,484 | $69.36 | $172.3K |
| Feb 18, 2026 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | SELL | 3,056 | $69.36 | $212.0K |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 5 neutral. Avg impact: 3.6/10.
NEUTRAL
8-K
2/10
Board member Alethia Young resigned effective June 8, 2026, citing a need to focus on other work com
Jun 9, 2026
NEUTRAL
CLUSTER
2/10
Two insiders at PTC Therapeutics sold a combined $220K of stock shortly after a strong Q1 earnings b
May 19, 2026
NEUTRAL
CLUSTER
2/10
Two PTCT insiders, including CEO Matthew Klein, sold a combined ~$115K in open-market sales within a
May 15, 2026
BULLISH
8-K
6/10
PTC Therapeutics reported positive 24-month interim data from the PIVOT-HD extension study of votopl
Apr 28, 2026
NEUTRAL
DEFA14A
3/10
PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors, including Jessi
Apr 20, 2026
BEARISH
CLUSTER
5/10
Three senior executives at PTC Therapeutics sold shares in a concentrated 7-day window, including a
Apr 8, 2026
NEUTRAL
CLUSTER
3/10
PTC Therapeutics CEO Matthew Klein sold $170,600 of stock in an open-market transaction, while Direc
Mar 13, 2026
BEARISH
CLUSTER
6/10
Three corporate insiders at PTC Therapeutics sold shares in a coordinated 7-day window, including th
Mar 9, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (76% buy). Based on 21 analysts: 5 strong buy, 11 buy, 4 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$93.93 mean target
+25.0% upside
Strong Buy (1.86)
$65.00 Low
$124.00 High
| Metric | Value |
|---|---|
| Current Price | $75.14 |
| Target Low | $65.00 |
| Target Mean | $93.93 |
| Target Median | $92.50 |
| Target High | $124.00 |
| # Analysts | 14 |
| Recommendation | Strong Buy (1.86) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.33 | $0.28 | $0.43 | 140.2% | +172.5% | — | $0.3B | 63.0% | 3 |
| Next Q 2026-09-30 |
$0.47 | $0.29 | $0.58 | 151.9% | +191.0% | — | $0.3B | 39.3% | 3 |
| Current FY 2026-12-31 |
$1.31 | $0.85 | $1.71 | -82.8% | +166.7% | 1↑ 0↓ | $1.2B | -32.2% | 3 |
| Next FY 2027-12-31 |
$2.78 | $1.29 | $4.18 | 111.9% | +14.5% | 1↑ 0↓ | $1.3B | 11.9% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.333 | |
| 7d ago | $0.333 | |
| 30d ago | $-0.460 | +0.793 |
| 60d ago | $-0.460 | +0.793 |
| 90d ago | $-0.460 | +0.793 |
7 analyst firms have rated this stock: 3 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Jefferies | UPGRADE | Hold | Buy |
| May 8, 2026 | TD Cowen | UPGRADE | Hold | Buy |
| May 8, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 30, 2026 | Jefferies | DOWNGRADE | Buy | Hold |
| Feb 23, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 20, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Feb 20, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | Barclays | UPGRADE | Equal-Weight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 11 | 4 | 1 | 0 | 76% | |
| May 1, 2026 | 4 | 11 | 6 | 1 | 0 | 68% | |
| Apr 1, 2026 | 4 | 10 | 6 | 1 | 0 | 67% | |
| Mar 1, 2026 | 6 | 10 | 5 | 1 | 0 | 73% | |
| Feb 1, 2026 | 6 | 10 | 5 | 1 | 0 | 73% | |
| Jan 1, 2026 | 6 | 9 | 6 | 1 | 0 | 68% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
short_volume
Short Volume: PTCT — 86.6% short (1.0M / 1.2M)
Short: 998,323 | Exempt: 0 | TRF Vol: 1,153,298 | Short Ratio: 86.6% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: PTCT — 82.9% short (0.6M / 0.7M)
Short: 612,471 | Exempt: 0 | TRF Vol: 738,542 | Short Ratio: 82.9% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: PTCT — 83.5% short (0.4M / 0.5M)
Short: 434,221 | Exempt: 800 | TRF Vol: 519,919 | Short Ratio: 83.5% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: PTCT — 65.9% short (0.4M / 0.6M)
Short: 405,996 | Exempt: 0 | TRF Vol: 616,493 | Short Ratio: 65.9% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: PTCT — 70.4% short (0.5M / 0.7M)
Short: 488,874 | Exempt: 5,846 | TRF Vol: 694,608 | Short Ratio: 70.4% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: PTCT — 82.6% short (1.4M / 1.7M)
Short: 1,389,742 | Exempt: 0 | TRF Vol: 1,683,112 | Short Ratio: 82.6% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_interest
FTD: PTCT — 11,393 shares ($0.7M) failed to deliver
Settlement: 20260508, Price: $64.49, FTD Value: $734,734.57, PTC THERAPEUTICS INC COM STK (
May 7, 2026
earnings_calendar
PTCT Q1 2026 Earnings After Market Close — 2026-05-07
May 1, 2026
Clinical Trial
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)
Phase Phase 3 — COMPLETED
May 1, 2026
clinical_trial_readout
Results Pending: Ataluren (Phase 3) — Completed 80d ago
Trial: Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)
Sponsor: PTC Therapeutics
Phase: Phase 3
Apr 29, 2026
short_volume
Short Volume: PTCT — 87.5% short (2.5M / 2.9M)
Short: 2,496,540 | Exempt: 1,155 | TRF Vol: 2,852,277 | Short Ratio: 87.5% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: PTCT — 80.1% short (0.7M / 0.9M)
Short: 710,331 | Exempt: 0 | TRF Vol: 886,293 | Short Ratio: 80.1% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
earnings_calendar
PTCT Q1 2026 Earnings After Market Close — 2026-04-23
Apr 13, 2026
Clinical Trial
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Apr 13, 2026
clinical_trial_readout
T-90d Trial Readout: PTC923 (Phase 3)
Trial: A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
Sponsor: PTC Therapeutics
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITIN
Apr 9, 2026
short_interest
FTD: PTCT — 48,960 shares ($3.5M) failed to deliver
Settlement: 20260409, Price: $71.26, FTD Value: $3,488,889.6, PTC THERAPEUTICS INC COM STK (
Apr 8, 2026
Clinical Trial
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
Phase Phase 3 — COMPLETED
Apr 6, 2026
clinical_trial_readout
T-90d Trial Readout: PTC923 (Phase 3)
Trial: A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
Sponsor: PTC Therapeutics
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITIN
Apr 1, 2026
Clinical Trial
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
Phase Phase 3 — TERMINATED